Abstract 798: SeroNet Pooling Project of immunocompromised populations


Kazemain Elham1,Figueiredo Jane1,Skarbinski Jacek2,McBride Russell3,Simon Viviana3,Karger Amy B.4,Lee F. Eun-Hyung5,Hirsch Fred R.3,Cox Andrea6,Klein Sabra7,Fan Rong8,Halene Stephanie8,Zidar David A.9,Crawford James M.10,Thyagarajan Bharat4,Gleason Charles11,Mathson Alex12,Srivastava Komal3,Moshele Puleng4,Amoss Toby13,Runnstrom Martin13,Linderman Susanne13,Rodilla Ananda M.3,Mack Philip C.3,Shyr Yu14,Yin Anna6,Shea Patrick6,VanOudenhove Jennifer15,Siddiqui Hinnah16,Wilson Brigid M.16,Elkin Eric P.2,Hsiao Crystal A.2,Ziemba Yonah10,Schleicher Cheryl B.10,Fox Sharon10,Kushi Lawrence H.2,Reckamp Karen1,Merchant Akil1,Merin Noah1


1. 1Cedars-Sinai Medical Center, Los Angeles, CA;

2. 2Kaiser Permanente Northern California, Oakland, CA;

3. 3Icahn School of Medicine at Mount Sinai, New York, NY;

4. 4University of Minnesota, Minneapolis, MN;

5. 5University of Emory, Atlanta, GA;

6. 6John Hopkins University School of Medicine, Baltimore, MD;

7. 7Johns Hopkins University Bloomberg School of Public Health, Baltimore, MD;

8. 8Yale School of Medicine, New Haven, CT;

9. 9Case Western Reserve University School of Medicine, Cleveland, OH;

10. 10Donald and Barbara Zucker School of Medicine at Hofstra/Northwell, Hempstead, Hempstead, NY;

11. 11Icahn School of Medicine at Mount Sinai, Los Angeles, CA;

12. 12University of Minnesota, Los Angeles, CA;

13. 13Emory University, Atlanta, GA;

14. 14Vanderbilt University, Nashville, TN;

15. 15Yale University School of Medicine, New Haven, CT;

16. 16Louis Stokes Cleveland Department of Veterans Affairs Medical Center, Cleveland, OH.


Abstract Introduction: COVID-19 vaccination substantially reduces morbidity and mortality associated with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection and severe illness. However, despite effective COVID-19 vaccines many questions remain about the efficacy of vaccines and the durability and robustness of immune responses, especially in immunocompromised persons. The NCI-funded Serological Sciences Network (SeroNet) is a coordinated effort including 11 sites to advance research on the immune response to SARS-CoV-2 infection and COVID-19 vaccination among diverse and vulnerable populations. The goals of the Pooling Project are: (1) to conduct real-world data (RWD) analyses using electronic medical records (EMR) data from four health care systems (Kaiser Permanente Northern California, Northwell Health, Veterans Affairs-Case Western, and Cedars-Sinai) to determine vaccine effectiveness in (a) cancer patients; (b) autoimmune diseases and (c) solid organ transplant recipients (SOTR); (2) to conduct meta-analyses of prospective cohort studies from eight SeroNet institutions (Cedars-Sinai, Johns Hopkins, Northwell Health, Emory University, University of Minnesota, Mount Sinai, Yale University) to determine post-vaccine immune responses in (a) lung cancer patients; (b) hematologic cancers/hematopoietic stem cell transplant (HSCT) recipients; (c) SOTR; (d) lupus. Methods: For our RWD analyses, data is extracted from EMR using standardized algorithms using ICD-10 codes to identify immunocompromised persons (hematologic and solid organ malignancy; SOTR; autoimmune disease, including inflammatory bowel disease, rheumatoid arthritis, and SLE). We use common case definitions to extract data on demographic, laboratory values, clinical co-morbidity, COVID-19 vaccination, SARS-CoV-2 infection and severe COVID-19, and disease-specific variables. In addition, we pool individual-level data from prospective cohorts enrolling patients with cancer and other immunosuppressed conditions from across network. Surveys and biospecimens from serology and immune profiling are collected at pre-specified timepoints across longitudinal cohorts. Results: Currently, we have EMR data extracted from 4 health systems including >715,000 cancer patients, >9,500 SOTR and >180,000 with autoimmune conditions. Prospective cohorts across the network have longitudinal data on >450 patients with lung cancer, >1,200 patients with hematologic malignancies, >400 SOTR and >400 patients with lupus. We will report results examining vaccine effectiveness for prevention of SARS-CoV-2 infection, severe COVID-19 and post-acute sequelae of COVID-19 (PAS-C or long COVID) in cancer patients compared to other immunocompromised conditions. Conclusion: Our goal is to inform public health guidelines on COVID-19 vaccine and boosters to reduce SARS-CoV-2 infection and severe illness in immunocompromised populations. Citation Format: Elham Kazemain, Jane Figueiredo, Jacek Skarbinski, Russell McBride, Viviana Simon, Amy B. Karger, F. Eun-Hyung Lee, Fred R. Hirsch, Andrea Cox, Sabra Klein, Rong Fan, Stephanie Halene, David A. Zidar, James M. Crawford, Bharat Thyagarajan, Charles Gleason, Alex Mathson, Komal Srivastava, Puleng Moshele, Toby Amoss, Martin Runnstrom, Susanne Linderman, Ananda M. Rodilla, Philip C. Mack, Yu Shyr, Anna Yin, Patrick Shea, Jennifer VanOudenhove, Hinnah Siddiqui, Brigid M. Wilson, Eric P. Elkin, Crystal A. Hsiao, Yonah Ziemba, Cheryl B. Schleicher, Sharon Fox, Lawrence H. Kushi, Karen Reckamp, Akil Merchant, Noah Merin. SeroNet Pooling Project of immunocompromised populations [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2023; Part 1 (Regular and Invited Abstracts); 2023 Apr 14-19; Orlando, FL. Philadelphia (PA): AACR; Cancer Res 2023;83(7_Suppl):Abstract nr 798.


American Association for Cancer Research (AACR)


Cancer Research,Oncology








Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3